Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 2

recruiting
3 974
countries
28
conditions
2 106

44 trials match your criteria

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of Ibrutinib Plus Ritonavir in Adults with Chronic Lymphocytic Leukemia, Lymphoplasmacytic Lymphoma, and Mantle Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib

Plasma cell myeloma refractory+1

Not yet recruiting

Dose optimization study of ibrutinib drug combination in adult patients with haematological diseases

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide

Acute lymphocytic leukaemia+6

Not recruiting

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine

Chronic lymphocytic leukaemia

Not recruiting

Study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia and TP53 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Acute myeloid leukaemia+10

Not recruiting

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Chronic lymphocytic leukaemia

Not recruiting

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Mantle cell lymphoma

Not recruiting

Study Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Cyclophosphamide

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.